HDAC Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy

BACKGROUND: Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that SAHA, a histone deacetylase (HDAC) inhibitor FDA-approved for cancer...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Xie, Min, Kong, Yongli, Tan, Wei, May, Herman, Battiprolu, Pavan K., Pedrozo, Zully, Wang, Zhao, Morales, Cyndi, Luo, Xiang, Cho, Geoffrey, Jiang, Nan, Jessen, Michael E., Warner, John J., Lavandero, Sergio, Gillette, Thomas G., Turer, Aslan T., Hill, Joseph A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984913/
https://ncbi.nlm.nih.gov/pubmed/24396039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.113.002416
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky